Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim, said that its latest topline data for their GLP-1 dual agonist strengthen our confidence in survodutide as a treatment candidate capable of addressing obesity and potentially offering targeted weight loss to help address connected conditions including liver disease
p38beta Mitogen- activated protein kinase signaling mediates exenatide-stimulated microglial beta-endorphin expression
( Response: We thank the commenters for their support

Liraglutide works by mimicking the natural GLP-1 hormone, which helps regulate blood sugar levels by: Stimulating insulin release when blood glucose levels are elevated Reducing glucagon secretion from the pancreas Slowing stomach emptying Increasing feelings of fullness and reducing appetite Medical Uses Liraglutide is approved for: Improving blood glucose control in adults and children aged 10 years and older with type 2 diabetes Reducing the risk of major cardiovascular events such as heart attack and stroke in adults with type 2 diabetes and cardiovascular disease Supporting long-term weight management when combined with a reduced-calorie diet and exercise Clinical Benefits Studies have shown that liraglutide may: Help lower HbA1c and improve glycemic control Promote weight reduction Improve satiety and reduce calorie intake Lower cardiovascular risk in some patients with type 2 diabetes Common Side Effects The most frequently reported side effects include: Nausea Vomiting Diarrhea Constipation Abdominal discomfort Injection-site reactions These gastrointestinal symptoms are usually more noticeable at the beginning of treatment and may decrease over time

Both rods and cones shed approximately 10% of their OS daily, and the discarded OS tips are ingested by the RPE 25
exceeding this limit may lead to Se toxicity (selenosis), characterized by gastrointestinal disturbances, hair loss, and neurological dysfunction [2]